{"nct_id":"NCT04209855","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression","status":"COMPLETED","status_verified_date":"2025-08","start_date":"2019-12-31","start_date_type":"ACTUAL","primary_completion_date":"2023-03-06","primary_completion_date_type":"ACTUAL","completion_date":"2024-10-29","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["ABBV"]}